The Cancer Prevention Master Guide (2026 Edition): I-PREVENT, the ROOT Protocol & the Complete Five-Layer Framework
- Metabolic Drivers of Cancer Risk
- Dietary Strategy
- Movement & Lifestyle
- Environmental Exposures & Sleep
- Core Nutraceuticals — Root 3
- Extended Nutraceuticals — Root 4–6 + I-PREVENT
- The Aged Garlic Extract (AGE) Upgrade
- Root 9 — Celecoxib, Ivermectin & Mebendazole
- The 2026 Evidence Debate: ASCO vs. the Repurposed-Drug Camp
Chapter 1 — The Case for Prevention
Most people absorb a version of the cancer story that goes roughly like this: cancer is mostly genetic, mostly bad luck, and best addressed through early detection and ever-better drugs. That story isn't wrong, but it's incomplete — and the gap between "incomplete" and "actionable" is exactly where a prevention framework earns its keep.
The scale of the problem is sobering. The World Health Organization estimates cancer claims roughly 10 million lives every year globally, and the American Cancer Society projected over 2 million new U.S. cases and more than 611,000 cancer deaths for 2024 alone. A 2024 Lancet Public Health analysis found 17 cancer types becoming more common in younger generations, with colorectal cancer now the leading cause of cancer death in men under 50 — a shift that has tracked closely with rising obesity, insulin resistance, sedentary living, and ultra-processed food consumption.
.png)
Meanwhile, treatment innovation — while real — has delivered smaller gains than headlines often suggest. Ladanie et al. (JAMA Network Open, 2020) found that newly approved cancer therapies over a recent fifteen-year period yielded an average overall survival improvement of just 2.4 months. Del Paggio et al. (JAMA Oncology, 2021) reported a similarly modest 3.4-month overall survival extension across a thirty-year retrospective of advanced clinical protocols. These incremental gains matter enormously for late-stage management, but they underscore a simple truth: the highest-leverage intervention against cancer is preventing its clinical manifestation in the first place.
A 2026 study in Nature Medicine estimated that at least 30 modifiable factors contribute to cancer risk, and that nearly 40% of cancer cases globally were preventable — three in ten cases in women, five in ten in men. Tobacco, high BMI, inactivity, and alcohol topped the list. That is the case for a layered, actionable framework rather than a single supplement or a single drug, and it is the reasoning behind everything that follows.
Chapter 2 — The Biology We're Targeting
To understand how to intervene, it helps to know what a cell must accomplish to become malignant. The updated Hallmarks of Cancer (Hanahan, Cancer Discovery, 2022) frame this as a set of acquired capabilities:
- Deregulating cellular energetics — abandoning efficient oxidative respiration in favor of rapid, inefficient sugar-burning (the Warburg effect).
- Tumor-promoting inflammation — co-opting immune cells to build blood vessels and clear space for growth.
- Non-mutational epigenetic reprogramming — silencing tumor-suppressor genes without altering the underlying DNA sequence.
- Polymorphic microbiomes — a gut-flora imbalance that impairs immune surveillance.
Many tumors are unusually glucose-dependent, and chronic hyperglycemia and hyperinsulinemia likely favor a permissive tumor microenvironment — the metabolic thread that runs through most of Layer 1 and Layer 2 of this framework.
The Mitochondrial-Stem Cell Connection (MSCC)
A newer, complementary theory worth understanding — though its evidence base is largely mechanistic and preclinical (CEBM Level 5) rather than confirmed in large human trials — is the Mitochondrial-Stem Cell Connection. Standard oncology has historically prioritized the Somatic Mutation Theory, which centers on DNA damage. The MSCC framework instead integrates Warburg's metabolic theory with stem cell biology: structural damage to mitochondria impairs normal oxidative phosphorylation, and stem cells forced into a baseline state of continuous anaerobic fermentation may transform into treatment-resistant cancer stem cells. Under this model, keeping mitochondria healthy and metabolically flexible is a foundational pillar of prevention — a theoretical lens that is consistent with, and helps explain, why the diet and metabolic interventions in Part II carry the strongest human evidence in this entire guide.
Chapter 3 — Methodology & Evidence Grading
Not all evidence is created equal, and this framework is explicit about the difference. We grade every claim using the Oxford Centre for Evidence-Based Medicine (CEBM) hierarchy, from strongest to weakest:
| CEBM Level | Evidence Type |
|---|---|
| Level 1 | Systematic reviews / meta-analyses of randomized controlled trials (RCTs) |
| Level 2 | Individual RCTs |
| Level 3 | Cohort studies, non-randomized controlled studies |
| Level 4 | Case series, case-control studies |
| Level 5 | Expert opinion, mechanistic/preclinical (cell-line, animal) data |
We reviewed well over 1,000 primary references across the source protocols folded into this guide. Preclinical and cell-line findings do not reliably predict human outcomes, and where a supplement or drug's evidence base is mostly Level 4–5, we say so explicitly rather than letting a strong mechanism story imply strong human proof. Editorial note: one of the source articles behind this guide used its own four-tier scale (Tier 1 = meta-analyses/RCTs down to Tier 4 = in-vitro data). We have re-expressed all of that material on the CEBM scale above for consistency across the OneDayMD Network rather than maintaining two parallel grading systems in one document.
Chapter 4 — Metabolic Drivers of Cancer Risk
Mammograms, colonoscopies, PSA tests, and CT scans detect disease that has already begun — they don't explain why it started. Layer 1 targets the modifiable, biologically plausible drivers that mainstream prevention messaging tends to under-emphasize.
| Modifiable Driver | Why It Matters |
|---|---|
| Obesity & hyperinsulinemia | Adipose tissue acts as an active endocrine/inflammatory organ, driving insulin resistance, elevated IGF-1, and chronic low-grade inflammation. |
| The Warburg effect | Many tumors are unusually glucose-dependent; chronic hyperglycemia/hyperinsulinemia likely favors a permissive tumor environment. |
| Ultra-processed foods | Linked to inflammation, gut dysbiosis, and insulin resistance (see Chapter 5). |
| Sarcopenia & inactivity | Muscle regulates glucose metabolism and inflammation; loss of muscle mass compounds insulin resistance. |
| Circadian disruption | IARC/WHO classifies shift work with circadian disruption as "probably carcinogenic to humans" (Group 2A). See Chapter 7. |
| Environmental exposures | Pesticides, microplastics, endocrine disruptors, and air pollution add oxidative and hormonal stress. See Chapter 7. |
Chapter 5 — Dietary Strategy
Malignant cells are disproportionately dependent on elevated blood glucose and insulin to fuel rapid replication, so managing metabolism through diet directly alters the systemic environment those cells depend on. Eliminating refined sugars, high-fructose corn syrup, and simple starches blunts the acute insulin and IGF-1 spikes that drive cellular growth pathways — the starting principle behind everything below.
- ACS 2020 guidelines: a healthy eating pattern rich in vegetables, whole fruit, legumes, and whole grains; limiting red/processed meat, sugar-sweetened beverages, and refined grains.
- Ultra-processed foods & sugar: a 2026 AACR-published study linked ultra-processed food intake to reduced survival after a cancer diagnosis. A February 2026 Nature Communications study found insulin resistance associated with a 25% higher risk across 12 cancer types (134% higher for uterine cancer). A 2026 BMJ analysis of the French NutriNet-Santé cohort tied food-preservative intake to higher overall and breast cancer rates, independent of age, weight, activity, smoking, and alcohol. A 2024 BMJ umbrella review of 45 pooled analyses (9.88 million participants) linked ultra-processed food intake to 32 distinct adverse health outcomes, cancer among them.
- Mediterranean & plant-forward patterns: a 2024 PLOS One umbrella review of 48 prior reviews found vegetarian/vegan diets significantly reduce gastrointestinal-cancer risk; a 2022 meta-analysis of 45 studies found daily olive oil consumers had a 31% lower risk of any cancer. Cruciferous vegetables (40–60 g/day, roughly half a cup of cooked broccoli) were linked to a 17% lower colon cancer risk in a 2025 analysis of 17 studies covering 639,539 people — those same vegetables supply the glucoraphanin that converts into sulforaphane (Chapter 9).
- Fiber: a 2023 umbrella review of 11 meta-analyses found the strongest fiber intake (25–29 g/day, per a 2019 Lancet analysis) associated with lower gastric, esophageal, ovarian, and endometrial cancer risk.
- Meat & cooking methods: IARC classifies processed meat as carcinogenic to humans; charring and high-heat cooking generate heterocyclic amines and PAHs. The red-meat/cancer link itself is less settled — pairing meat with fiber-rich vegetables appears to attenuate risk.
- Fasting, keto, low-carb (controversial): a 2024 Nutrients review found overnight fasting may help but excessive fasting can harm quality of life; a Japanese cohort found low-carb diets raised colorectal/lung cancer risk while lowering gastric cancer risk. Time-restricted feeding — an 8-hour eating window paired with a 16-hour fast — is thought to promote autophagy, the process by which cells clear damaged components and organelles. None of this is appropriate if underweight.
- Coffee: a 2021 Nature umbrella review found coffee inversely associated with liver cancer and basal cell carcinoma risk.
Chapter 6 — Movement & Lifestyle
- Tobacco: the single largest modifiable factor — nearly 20% of all cancer cases and close to 30% of cancer deaths.
- Exercise: a landmark 17-year, 880-patient NEJM (2025) randomized trial found a structured 3-year exercise prescription outperformed general activity advice at preventing colon cancer recurrence after high-risk stage 2/3 disease — a result that reportedly stunned the ASCO audience it was presented to. A 2025 JNCI analysis found moderate-to-vigorous activity improved survival across 10 cancer types. As a practical target: aim for a minimum of 150 minutes per week of moderate-intensity (Zone 2) cardio to maximize mitochondrial density and efficiency, plus 2–3 dedicated resistance-training sessions weekly — muscle tissue acts as a metabolic sink for excess glucose. Strength-training meta-analyses show a J-shaped benefit curve, with maximum risk reduction (10–20%) around 30–60 minutes/week and diminishing or reversed benefit above roughly 140 minutes/week.
- Alcohol: a 2021 Nature umbrella review confirmed alcohol's positive association with postmenopausal breast, colorectal, esophageal, head & neck, and liver cancer risk.
Chapter 7 — Environmental Exposures & Sleep
Supplements cannot fix a toxic lifestyle or continuous chemical exposure, and this is the piece of Layer 1 most often left out of cancer-prevention writing altogether.
Endocrine-Disrupting Chemicals
Chronic exposure to endocrine-disrupting chemicals (EDCs) — bisphenol-A (BPA) in thermal cash-register receipts and rigid plastics, and per- and polyfluoroalkyl substances (PFAS) in non-stick cookware — can stimulate hormone-receptor-positive cells, compounding baseline cancer risk over decades of low-level exposure. Practical reductions (glass or stainless containers, avoiding thermal-paper receipt handling where feasible, PFAS-free cookware) are low-cost, low-risk additions to any layer of this framework.
Sleep as an Active Repair State
Sleep is not a passive luxury; it is an active physiological repair state. Deep slow-wave sleep regulates systemic immune function, and the nocturnal release of melatonin from the pineal gland serves as a powerful natural antioxidant that helps clear brain and tissue space, preserving long-term DNA integrity. This is also why circadian disruption (Chapter 4) carries an IARC Group 2A "probably carcinogenic" classification for shift work specifically — sleep and circadian rhythm are not a wellness add-on but a mechanistic extension of the metabolic case made throughout Part II.
Chapter 8 — Core Nutraceuticals: Root 3 (Layer 2)
Drs. Marik and Hope built the ROOT Protocol as a stepwise, evidence-ranked framework that adds one agent at a time. Root 3 — this layer — is the three-agent foundation they consider a reasonable starting point for essentially everyone, from young adults to centenarians; we add omega-3 alongside it given how tightly its trial evidence is intertwined with vitamin D3's.
| Agent | Key Human Evidence | Primary Mechanism |
|---|---|---|
| Green Tea EGCG | Minnesota Green Tea Trial (RCT, n=1,075): reduced mammographic breast density in postmenopausal women aged 50–55. | Blocks GLUT1/hexokinase-2 (disrupting the Warburg effect); shifts tumor-associated macrophages from pro-inflammatory M2 toward antitumor M1; inhibits DNA methyltransferase enzymes to help reactivate silenced tumor-suppressor genes; also inhibits angiogenesis. |
| Curcumin | 21-study human review (16/21 trials positive); 50+ registered clinical trials, most ongoing. | AKT/mTOR and Wnt/β-catenin inhibition; blocks the COX-2 enzyme and downregulates NF-κB inflammatory signaling (TNF-alpha, IL-6); induces apoptosis across many cell lines. |
| Vitamin D3 (+ K2) | DO-HEALTH RCT: adjusted HR 0.39 for invasive cancer in the combined D3+omega-3+exercise arm. VITAL trial: HR 0.72 for cancer mortality (a 15–20% mortality reduction). A 2025 meta-analysis of 50 studies (1.3M+ participants) linked low D3 to higher colorectal cancer risk. | Behaves like a systemic steroid hormone regulating 200+ genes tied to differentiation and proliferation; stabilizes IκBα (blunting NF-κB); activates Nrf2; upregulates DNA-repair genes (TP53, BRCA1, ATM); inhibits VEGF-driven angiogenesis; enhances macrophage and NK-cell activation. K2 (menaquinone-7) directs the calcium D3 helps absorb into bone rather than blood vessels. |
| Omega-3 (EPA/DHA) | DO-HEALTH synergy data; CAPFISH-3 RCT (2024): a high-omega-3/low-omega-6 diet plus fish oil reduced Ki-67 (a prostate-cancer progression biomarker) over one year. | Competes with pro-inflammatory omega-6 and displaces arachidonic acid from cell membranes, helping switch off NF-κB; activates PPARs; can trigger ferroptosis in acidic tumor microenvironments. |
Practical notes: curcumin needs a bioavailable extract — a phytosomal complex (e.g., Meriva) or liposomal delivery, or at minimum taken with fat or piperine — since raw turmeric is only about 3% curcumin by weight with roughly 1% bioavailability. Target vitamin D3 serum levels of roughly 40–60 ng/mL. Use a low-oxidation ("low-TOTOX"), heavy-metal-tested omega-3 product at 2,000–4,000 mg/day of combined EPA/DHA.
Chapter 9 — Extended Nutraceuticals: Root 4–6 + I-PREVENT (Layer 3)
Root 4 (omega-3, covered above) is positioned by Marik and Hope as the basic protocol for older adults, since most cancers occur after age 65. Root 5 and Root 6 are for those at elevated but non-hereditary risk. We've merged these with I-PREVENT's own broader supplement list, since the two overlap heavily in both agents and mechanism.
| Agent | Key Evidence | Mechanism |
|---|---|---|
| Berberine | 6-year RCT follow-up (Cell Reports Medicine, 2025): colorectal adenoma recurrence 34.7% vs. 52.1% (placebo). | Potent AMPK activation (metformin-like), which suppresses the mTOR pathway that cancer cells exploit for uncontrolled growth; BAX↑/BCL2↓; anti-angiogenic via VEGF/MMP inhibition; improves insulin sensitivity. |
| Sulforaphane | Mechanistic + cruciferous-vegetable epidemiology (17% lower colon cancer risk, Chapter 5). | Converted from dietary glucoraphanin; HDAC/DNMT inhibition helps reactivate silenced tumor-suppressor genes; triggers caspase-mediated apoptosis. |
| Vitamin C (oral vs. IV) | 76-meta-analysis umbrella review: reduced esophageal, gastric, cervical, and lung cancer risk at 50–100 mg/day dietary increments. | Oral doses above ~2,000 mg are largely excreted by intestinal absorption limits and act only as a transient antioxidant. Physician-administered intravenous vitamin C bypasses the gut entirely, reaching blood concentrations up to 100× higher, at which point it behaves as a pro-oxidant — reacting with iron to generate hydrogen peroxide selectively within tissue, a mechanism under study for tumor-selective oxidative stress. This is a physician-supervised intervention, not a self-directed one; screening for G6PD deficiency is standard practice before high-dose IV protocols given the hemolysis risk. |
| Magnesium | Swedish Mammography Cohort (61,433 women) and WHI (140,601 women): higher intake linked to lower colorectal cancer risk. Vitamins & Lifestyle cohort: deficiency linked to pancreatic cancer. | Mandatory cofactor for 300+ enzymatic reactions, including glucose/insulin signaling regulation and nucleotide excision repair — the DNA-repair mechanism that corrects mutations. |
| Zinc | Retrospective studies linking deficiency to hepatocellular carcinoma and Barrett's esophagus progression. | Enzymatic/immune cofactor and structural core of "zinc-finger" protein motifs that regulate cellular transcription and back up the p53 gene, the "guardian of the genome." |
| Garlic (dietary) | 543,220-participant study: lower stomach cancer risk with high allium intake; 2–5g fresh garlic/day recommended. | Organosulfur-compound activity; see also the concentrated Aged Garlic Extract upgrade in Chapter 10. |
| Melatonin | 2005 systematic review (10 RCTs, n=643 solid-tumor patients): 34% reduced 1-year mortality. | Antioxidant; p53↑; anti-angiogenic. Its nocturnal pineal release is also central to the sleep-repair mechanism described in Chapter 7. Use caution in hormone-sensitive cancers. |
| Probiotics / gut microbiome | 2018 findings: gut microbes regulate antitumor immune responses in the liver; certain bacteria improve response to anticancer drugs. | Gut-liver immune axis modulation. |
| Quercetin | Phase I trial + preclinical senolytic data. | Senolytic, pro-apoptotic. Caution: interacts with anticoagulants, some antibiotics, corticosteroids, and digoxin. |
| Carotenoids | 2024 umbrella review (51 articles, 198 meta-analyses): dietary intake inversely associated with cancer risk — but high-dose isolated supplements (especially beta-carotene) increased risk. | Food-first only; avoid isolated high-dose supplementation. |
| Nicotinamide | 2025 JAMA Dermatology retrospective (33,822 veterans): decreased risk of 3 skin cancer types. | DNA-repair support. |
| Beta-glucans | Mechanistic + NK-cell activation data (shiitake, maitake, oyster mushrooms). | Complement/dectin-1 receptor activation. |
| Molecular Hydrogen | 2023 systematic review (27 studies): improved survival as adjuvant therapy. Little evidence for primary prevention specifically. | A selective antioxidant that neutralizes the highly damaging hydroxyl radical while sparing helpful signaling radicals — but this selectivity may also blunt ROS-dependent chemo/radiotherapy effects, so timing matters during active treatment. |
Chapter 10 — The Aged Garlic Extract (AGE) Upgrade (Layer 4)
Aged Garlic Extract is not the same as raw garlic or standard garlic supplements. It's produced through a roughly 20-month aqueous-ethanol aging process that converts unstable compounds like allicin into stable, odorless organosulfur compounds such as S-allyl cysteine. In Marik and Hope's framework, any tier can be upgraded to its "+" variant by adding AGE — and I-PREVENT's own supplement list reaches the same conclusion independently.
- A landmark 2004 RCT (~5,000 participants) found AGE reduced stomach cancer incidence by 52%, strongest in men.
- A 22-year BMJ follow-up (2019) found participants still had 34% lower cancer mortality 17 years after stopping supplementation.
- A separate RCT in colorectal adenoma patients found high-dose AGE over one year significantly reduced adenoma number and size versus low-dose AGE.
Proposed mechanisms include reduced IGF-1, activated autophagy, NF-κB suppression, and up to a 300% boost in Natural Killer cell activity. Standard dosing is 600 mg twice daily. AGE can increase bleeding risk when combined with anticoagulants or antiplatelet drugs.
Chapter 11 — Root 9: Celecoxib, Ivermectin & Mebendazole
This is where the framework shifts from over-the-counter nutraceuticals to prescription drugs — and where Marik and Hope are explicit that the tier is scoped to a specific population: people with a confirmed inherited cancer syndrome, managed by a physician familiar with hereditary cancer risk. Not the general population. Not a self-directed protocol.
| Syndrome | Gene | Approx. Lifetime Risk |
|---|---|---|
| Hereditary breast/ovarian cancer | BRCA1/BRCA2 | Up to ~70% breast cancer risk in women |
| Li-Fraumeni syndrome | TP53 | >50% risk of multiple cancers |
| Lynch syndrome | Mismatch-repair genes | 50–70% colorectal; up to 60% endometrial (women) |
| Familial adenomatous polyposis (FAP) | APC | Near 100% colorectal cancer without intervention |
Germline mutations of this kind account for roughly 5–10% of all cancers. For carriers, Root 9 layers three additional agents on top of Layers 2–3:
- Celecoxib — a COX-2 inhibitor already FDA-approved as adjunctive therapy for FAP; 400 mg twice daily produced a 28% reduction in colorectal polyps vs. 5% with placebo in trials. This is the one Root 9 component with an established, FDA-recognized dosing regimen for a hereditary-cancer indication.
- Ivermectin — an FDA-approved antiparasitic. Preclinical work suggests it may inhibit WNT-TCF signaling (relevant to FAP-associated colorectal cancer), suppress PAK1 kinase (relevant to BRCA-mutated breast cancer models), and induce mitochondrial oxidative stress in pancreatic cancer cell lines — laboratory/animal findings, not confirmed human prevention outcomes.
- Mebendazole — an FDA-approved anthelmintic. In the ApcMin/+ mouse model of FAP it reduced intestinal tumor counts by 56% alone, and up to 90% combined with sulindac. A phase 2a human trial found doses up to 4 g/day tolerable in advanced GI cancer, though disease progressed in all participants.
Important safety note: neither ivermectin nor mebendazole has an established human dosing regimen for cancer prevention, and we deliberately do not provide one here. Dosing needs to be individualized by a physician. Dr. Marik himself has reinforced this: in a June 2026 note on our resource pages, he specifically flagged a widely circulated high-dose ivermectin cancer protocol as "a potentially toxic dosing protocol which we do NOT recommend." That caution, from one of the therapy's own prominent advocates, deserves serious weight regardless of where you land on the broader debate (Chapter 12).
Chapter 12 — The 2026 Evidence Debate: ASCO vs. the Repurposed-Drug Camp
Any honest discussion of Layer 5 has to include where organized oncology currently stands. In a Clinical Notice published in June 2026, ASCO stated there is no robust, peer-reviewed clinical evidence that either ivermectin or fenbendazole is safe or effective for treating any human malignancy, and cautioned that both should stay within the regulatory safeguards of a formal clinical trial rather than being used as a cancer treatment or adjunct outside one. ASCO's Chief Medical Officer specifically flagged social-media and podcast-driven misinformation as a safety concern, while acknowledging legitimate human trials remain in early stages — including a phase I/II ivermectin-plus-checkpoint-inhibitor study in metastatic triple-negative breast cancer, and the phase II ICONIC trial.
ICONIC trial status update (verified September 2026): NCT07487805, sponsored by the University of Florida, remains not yet recruiting as of its most recent July 2026 status verification, with an estimated start date of September 2026 and an estimated primary completion date of September 2027. Readers should not assume enrollment has begun.
Dr. Marik has pushed back on ASCO's framing, arguing that demanding large randomized trials before considering low-cost, off-patent therapies sets a bar that mainly well-funded pharmaceutical products can clear, and that carefully tracked observational cohorts can still generate meaningful signal while formal trials catch up.
We think both points are worth holding onto at once. ASCO's underlying factual claim — that no large, peer-reviewed human trial currently demonstrates ivermectin or fenbendazole benefit in cancer — is accurate as of this writing, and the toxicity concern is real: unsupervised, high-dose regimens circulating online use doses well above those approved for parasitic infections. At the same time, Layer 5 as defined here already narrows its drug component to a specific, physician-supervised, hereditary-risk population — a meaningfully different (and more conservative) proposal than the general "take ivermectin for cancer" claims ASCO's notice addresses. Treat Layer 5 as an open scientific question to raise with an oncologist or integrative oncologist, not a settled, self-directed regimen.
Chapter 13 — Dosing & Safety Reference Table
| Agent | Layer | Upper Safety Threshold / Range | Key Caution |
|---|---|---|---|
| EGCG (green tea extract) | 2 | Up to ~800 mg/day | Rare hepatotoxicity above 800 mg/day; take with food; mild GI upset |
| Curcumin | 2 | Up to ~8 g/day extract | May interact with anticoagulants/antiplatelets; take with fat or piperine, or use a phytosomal/liposomal form |
| Vitamin D3 | 2 | Up to ~5,000 IU/day | Monitor serum calcium; avoid hypercalcemia at high sustained intake; pair with K2 and magnesium |
| Omega-3 (EPA/DHA) | 2 | Bleeding risk rises above ~3 g/day | Use a low-TOTOX product; caution with anticoagulants |
| Berberine | 3 | Per product label | Metformin-like effect; caution combining with diabetes medications |
| Oral Vitamin C | 3 | Diminishing returns above ~2,000 mg/day | Excess is simply excreted; not equivalent to IV dosing |
| Intravenous Vitamin C | 3 | Physician-administered only | Screen for G6PD deficiency before high-dose IV protocols (hemolysis risk) |
| Melatonin | 3 | 1–2 mg (extended release) at night | Caution in hormone-sensitive cancers (breast, prostate) |
| Quercetin | 3 | Per product label | Interacts with anticoagulants, some antibiotics, corticosteroids, digoxin |
| Aged Garlic Extract | 4 | 600 mg twice daily | Increased bleeding risk with anticoagulants/antiplatelets |
| Celecoxib | 5 | 400 mg twice daily (FAP-specific, FDA-recognized) | Physician-prescribed only; cardiovascular/GI risk profile of COX-2 inhibitors applies |
| Ivermectin | 5 | No established cancer-prevention dose — not provided here | Physician-supervised, hereditary-syndrome context only; avoid unsupervised high-dose protocols |
| Mebendazole | 5 | No established cancer-prevention dose — not provided here | Physician-supervised, hereditary-syndrome context only |
Reported adverse events across the Layer 2 core agents combined were mostly mild in the underlying trial data: gastrointestinal symptoms (~15%), headache (~5%), and fatigue (~3%). Anyone pregnant, immunocompromised, or on anticoagulant therapy should check with a physician before starting any layer above the diet/lifestyle foundation.
Chapter 14 — Which Layers Are Right for You?
| Your Situation | Suggested Layers |
|---|---|
| Generally healthy, no known risk factors | Layer 1 + Layer 2 |
| Age 65+ | Layers 1–2, consider adding Layer 3 agents |
| Elevated but non-hereditary risk (family history without a confirmed mutation, prior polyps, metabolic syndrome) | Layers 1–3, discuss Layer 4 with your physician |
| Confirmed hereditary cancer syndrome (BRCA1/2, Lynch, FAP, Li-Fraumeni) under specialist care | Layers 1–4; discuss Layer 5 explicitly with a physician experienced in hereditary cancer risk |
| Currently in active cancer treatment or a survivor | This is a prevention framework, not a treatment protocol. Coordinate any of the above with your oncology team, and consult our treatment-focused resources separately. |
Chapter 15 — Key Takeaways
- Cancer prevention in 2026 is increasingly framed around metabolic health, chronic inflammation, and environmental exposure — not genetics alone, and the Hallmarks of Cancer and Mitochondrial-Stem Cell Connection frameworks both point back to the same metabolic terrain.
- Layer 1 (diet, weight, exercise, tobacco/alcohol avoidance, environmental exposure, and sleep) carries the broadest and strongest human evidence of any layer in this framework, including a landmark NEJM trial showing structured exercise outperforming general advice at preventing colon cancer recurrence.
- Layer 2 (EGCG, curcumin, vitamin D3, omega-3) is anchored by the DO-HEALTH and VITAL randomized trials — the strongest human-trial support of any nutraceutical tier.
- Layers 3–4 add a wider set of agents with plausible mechanisms and growing, but not always definitive, human data.
- Layer 5 (celecoxib, ivermectin, mebendazole) is explicitly designed for people with confirmed hereditary cancer syndromes under specialist supervision — not a general-population or self-directed protocol.
- ASCO's 2026 Clinical Notice and Dr. Marik's own caution about high-dose ivermectin protocols both deserve serious weight; this is an active, unresolved evidence debate, not a settled question, and the ICONIC trial has not yet begun enrolling as of this update.
- This framework is for cancer prevention in healthy or at-risk adults — it is not a substitute for oncology care in anyone already diagnosed.
Chapter 16 — Using This Guide With AI Assistants
Chapter 17 — Frequently Asked Questions
I-PREVENT is OneDayMD's own diet-lifestyle-and-broad-supplement framework, running since 2022. ROOT is Dr. Paul Marik and Dr. Justus Hope's sequential nutraceutical-to-prescription-drug escalation ladder. This master guide merges both, plus a third standalone I-PREVENT mechanistic deep-dive, into one five-layer system organized as an ebook so readers don't have to reconcile three separate documents themselves.
A tiered framework starting with EGCG, curcumin, and vitamin D3 (Root 3), adding omega-3, berberine, and sulforaphane through Root 6, and finally adding celecoxib, ivermectin, and mebendazole at Root 9 for people with hereditary cancer syndromes.
A theoretical framework, still largely mechanistic (CEBM Level 5) rather than confirmed in large human trials, proposing that mitochondrial damage forces stem cells into a fermentation-dominant metabolic state that can predispose them to transform into treatment-resistant cancer stem cells. It complements, rather than replaces, the mainstream Somatic Mutation Theory.
Individual components have trial or preclinical support of varying strength; the combined framework itself hasn't been tested as a single protocol in a large randomized trial, and Layer 5's drug component remains investigational.
Only people with a confirmed hereditary cancer syndrome (e.g., BRCA1/2, Lynch syndrome, FAP), working with a physician experienced in hereditary cancer risk.
Not as of this update. NCT07487805 was listed as not yet recruiting in its July 2026 status verification, with an estimated September 2026 start at the University of Florida.
They're considered a contributing, cumulative factor rather than a dominant one — endocrine-disrupting chemicals can stimulate hormone-receptor-positive cells over decades of low-level exposure. They belong in a comprehensive prevention framework, but diet, weight, exercise, tobacco, and alcohol carry substantially stronger evidence of impact.
This is a prevention framework for healthy or at-risk adults, not a treatment protocol. If you're in active treatment or are a survivor, discuss any of these layers with your oncology team first.
Layer 1. Diet, weight management, exercise, sleep, and avoiding tobacco/excess alcohol have the largest, most consistent body of human evidence of any layer in this framework.
Chapter 18 — Medical Disclaimer, Disclosures & References
Medical disclaimer: This guide is for educational purposes only and does not constitute medical advice. Nothing here should be used to start, stop, or replace any cancer treatment or screening plan. Decisions about supplements or off-label/repurposed drug use — especially celecoxib, ivermectin, mebendazole, and intravenous vitamin C — should be made with a qualified physician familiar with your medical history, current treatments, and, where relevant, your genetic risk profile.
Conflict of interest disclosure: OneDayMD maintains affiliate relationships with The Wellness Company (referral code ONEDAYMD) and Amazon Associates. Some product links on this site are affiliate links, meaning we may earn a commission at no additional cost to you. This did not influence the content, evidence grading, or safety cautions presented above. We have no financial relationship with Dr. Marik, Dr. Hope, or the Independent Medical Alliance.
Selected references: Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31–46. · Ladanie, A., et al. (2020). Evaluating Overall Survival Benefits of New Cancer Treatments. JAMA Network Open, 3(11). · Del Paggio, J.C., et al. (2021). Delivery of Meaningful Cancer Care over Three Decades. JAMA Oncology, 7(4), 541–549. · Manson, J.E., et al. (2019). Vitamin D Supplementation and Cancer Mortality: Results from VITAL. NEJM, 380(1), 33–44. · Full reference lists for individual agents are available in the source articles linked below.
Comments
Post a Comment